Platelet-Rich Plasma (PRP) in Breast Cancer Patients: An Application Analysis of 163 Sentinel Lymph Node Biopsies.
Adult
Aged
Breast Neoplasms
/ diagnosis
Female
Humans
Lymph Node Excision
/ methods
Lymphatic Metastasis
/ prevention & control
Middle Aged
Neoplasm Recurrence, Local
/ prevention & control
Platelet-Rich Plasma
/ physiology
Sentinel Lymph Node
/ pathology
Sentinel Lymph Node Biopsy
Survival Analysis
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
06
2020
revised:
26
08
2020
accepted:
05
10
2020
entrez:
4
11
2020
pubmed:
5
11
2020
medline:
11
5
2021
Statut:
epublish
Résumé
Literature shows platelet-rich plasma (PRP) to improve overall outcomes in orthopedics, dermatology, ophthalmology, gynecology, and plastic surgery. Data on oncological patients is very limited. Only one publication is available on PRP in breast cancer patients. This work evaluated PRP in sentinel node biopsy procedures for breast cancer patients in terms of complication rates and oncological short-term follow-up. The evaluated PRP was ACP®, i.e., autologous conditioned plasma by Arthrex®. Between 2015 and 2018, 163 patients were offered to receive an ACP®/PRP injection in their lymph node biopsy site. Recruitment resulted in an approximate one-to-one ratio for analysis. Endpoints were major (revision) and minor (seroma, hematoma, and infection) complications rates as well as distant metastases, local recurrence, and overall survival. Median follow-up was 30 months. Complication rates and oncological follow-up showed PRP to be applicable to use in a sentinel node biopsy scenario in breast cancer patients. There were 0 revisions in the ACP®/PRP group and 1.2% revisions in the control group (not significant). Oncological follow-up showed zero (0) distant metastases and local recurrences as well as a 100% 30-month overall survival. This is the first analysis of ACP®/PRP used in breast cancer patients in a sentinel node biopsy setting worldwide. PRP does not seem to increase rates of local recurrence within this 30-month follow-up time frame. Also, trend towards decreasing complication rates could be shown.
Identifiants
pubmed: 33145346
doi: 10.1155/2020/3432987
pmc: PMC7599401
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3432987Informations de copyright
Copyright © 2020 C. Eichler et al.
Déclaration de conflit d'intérêts
This is an investigator driven study. The authors have no conflicts of interest.
Références
Zhonghua Yi Xue Za Zhi. 2014 Jul 22;94(28):2169-74
pubmed: 25331465
In Vivo. 2019 Sep-Oct;33(5):1559-1564
pubmed: 31471405
Orthop Rev (Pavia). 2014 Sep 18;6(3):5405
pubmed: 25317308
Breast Care (Basel). 2019 Dec;14(6):382-387
pubmed: 31933584
Exp Eye Res. 2015 Jun;135:118-26
pubmed: 25708868
Wound Repair Regen. 2019 May;27(3):268-276
pubmed: 30693614
Turk J Obstet Gynecol. 2019 Dec;16(4):228-234
pubmed: 32231853
Diagnostics (Basel). 2020 Mar 28;10(4):
pubmed: 32231127
In Vivo. 2017 Jul-Aug;31(4):677-682
pubmed: 28652438
Arthroscopy. 2015 Jan;31(1):125-35
pubmed: 25278352
Stem Cell Res Ther. 2012 Feb 22;3(1):7
pubmed: 22356811
Anticancer Res. 2019 May;39(5):2599-2605
pubmed: 31092458
Biomed Res Int. 2015;2015:630601
pubmed: 25879032
Plast Reconstr Surg Glob Open. 2015 Jul 08;3(6):e439
pubmed: 26180740
J Korean Med Sci. 2014 Jun;29(6):751-7
pubmed: 24932073
Pharmaceuticals (Basel). 2020 Mar 18;13(3):
pubmed: 32197544
Plast Reconstr Surg. 2004 Nov;114(6):1502-8
pubmed: 15509939
Biomed Res Int. 2014;2014:890630
pubmed: 25302310
Biomed Res Int. 2020 Mar 7;2020:2642439
pubmed: 32219128
Skin Therapy Lett. 2019 Sep;24(5):1-6
pubmed: 31584784
BMJ. 2013 Jun 18;346:f3012
pubmed: 23778427